Tolvaptan
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB06212 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | polycystic kidney disease 3 with or without polycystic liver disease | KG + DL |
| 2 | renal-hepatic-pancreatic dysplasia | KG + DL |
| 3 | karyomegalic interstitial nephritis | KG + DL |
| 4 | thoracic malformation | KG + DL |
| 5 | Joubert syndrome with renal defect | KG + DL |
| 6 | adult familial nephronophthisis-spastic quadriparesia syndrome | KG + DL |
| 7 | Ambras type hypertrichosis universalis congenita | KG + DL |
| 8 | hypertrichosis (disease) | KG + DL |
| 9 | malformation syndrome with odontal and/or periodontal component | KG + DL |
| 10 | syndrome with a Dandy-Walker malformation as major feature | KG + DL |
| 11 | isolated genetic hair shaft abnormality | KG + DL |
| 12 | homozygous familial hypercholesterolemia | KG + DL |
| 13 | Joubert syndrome with oculorenal defect | KG + DL |
| 14 | Meckel syndrome, | KG + DL |
| 15 | syndrome with limb duplication, polydactyly, syndactyly, and/or hyperphalangy | KG + DL |
| 16 | hypoalphalipoproteinemia | KG + DL |
| 17 | autosomal dominant polycystic kidney disease type 1 with tuberous sclerosis | KG + DL |
| 18 | congenital pulmonary lymphangiectasia | KG + DL |
| 19 | multiple endocrine neoplasia | KG + DL |
| 20 | polycystic liver disease | KG + DL |
| 21 | 16q24.1 microdeletion syndrome | KG + DL |
| 22 | primary interstitial lung disease specific to childhood | KG + DL |
| 23 | congenital alveolar capillary dysplasia | KG + DL |
| 24 | isolated pulmonary capillaritis | KG + DL |
| 25 | cranioectodermal dysplasia | KG + DL |
| 26 | RHYNS syndrome | KG + DL |
| 27 | gastrocutaneous syndrome | KG + DL |
| 28 | nephrogenic diabetes insipidus | KG + DL |
| 29 | familial generalized lentiginosis | KG + DL |
| 30 | psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome | KG + DL |
| 31 | Joubert syndrome with hepatic defect | KG + DL |
| 32 | Senior-Boichis syndrome | KG + DL |
| 33 | renal tubule disease | KG + DL |
| 34 | isolated encephalocele | KG + DL |
| 35 | Moynahan syndrome | KG + DL |
| 36 | sitosterolemia | KG + DL |
| 37 | acromelanosis | KG + DL |
| 38 | congenital multiple café-au-lait macules-increased sister chromatid exchange syndrome | KG + DL |
| 39 | pulmonary arterial hypertension | KG + DL |
| 40 | osteopathia striata-pigmentary dermopathy-white forelock syndrome | KG + DL |
| 41 | pulmonary arteriovenous malformation (disease) | KG + DL |
| 42 | rhabdoid tumor | KG + DL |
| 43 | pulmonary arterial hypertension associated with congenital heart disease | KG + DL |
| 44 | renal fibrosis | KG + DL |
| 45 | dermatofibrosarcoma protuberans | KG + DL |
| 46 | laterality defects, autosomal dominant | KG + DL |
| 47 | familial caudal dysgenesis | KG + DL |
| 48 | leukonychia totalis-acanthosis-nigricans-like lesions-abnormal hair syndrome | KG + DL |
| 49 | autosomal dominant polycystic liver disease | KG + DL |
| 50 | benign neoplasm of adrenal gland | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.